secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2025-02-11T23:59:59+00:00
Accession:  0001104659-25-011155
Event type: other_material
Sentiment:  negative
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager delays SOD1 ALS IND filing; switches payload after NHP data; cash runway to mid-2027
--------------------------------------------------------------------------------

- VY9323 IND/CTA filing no longer expected mid-2025 due to need for alternate payload after 3-month NHP data.
- Capsid unchanged; decision based on achieving desired product profile for SOD1 ALS gene therapy.
- Other programs unaffected: Neurocrine GBA1 and Friedreich’s ataxia IND filings still on track for 2025.
- Tau silencing program VY1706 IND expected in 2026; preclinical activity levels achieved.
- Cash and equivalents plus collaboration reimbursements fund operations into mid-2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000110465925011155/0001104659-25-011155-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000110465925011155/tm256087d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-011155

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer